IJ:
>> Way OT <<
FDA needs, IMO, to increasingly focus on life style drugs. They need to focus on a society that is driven by [what I consider to be] the insane, ever-increasing need for productivity. They need to focus on the boss who wants his employees healthy so that he can be competitive. They need to focus on NBIX the employee who can't afford NBIX a night without sleep, or to NBIX wake up groggy before work. They need to focus on disease transmission in a world where a person with Ebola can get on an airplane and fly to Seattle or Paris for an interview or where the aerosol from a single sneeze can infect several coworkers in the new-age, crowded and stressful work environment. They need to focus on keeping the worker healthy as they join the competition to be most productive. This sort of discussion *is*, IMO, on-topic. I've addressed it before in the BVF thread, if not here.
I went one step further and *did* go off-topic. I'm a radical environmentalist who believes in using less. You drew the parallel between health and competitive advantage. I draw the parallel between competitive advantage -- "capitalism" -- and a predominant role in the destruction of Earth.
I'm also a microbiologist. "Germs" will, on occasion, win. I want to delay that "inevitable" for at least a couple of generations, and we need a proactive FDA.
Back to on-topic..... what do you imagine that the competitive advantage of VP68881, the plec backup, might be? What will the approval of Clarinex do to the stock Monday morning, if anything?
Rick |
